Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 12/2009

01-12-2009 | Article

Regression of diabetic complications by islet transplantation in the rat

Authors: A. Remuzzi, R. Cornolti, R. Bianchi, M. Figliuzzi, C. Porretta-Serapiglia, N. Oggioni, V. Carozzi, L. Crippa, F. Avezza, F. Fiordaliso, M. Salio, G. Lauria, R. Lombardi, G. Cavaletti

Published in: Diabetologia | Issue 12/2009

Login to get access

Abstract

Aims/hypothesis

Type 1 diabetes is a chronic disease leading to complications such as peripheral neuropathies, nephropathy and cardiovascular disease. Pancreatic islet transplantation is being extensively investigated for blood glucose control in animals and in human type 1 diabetic patients, but the question of whether it can reverse long-term diabetic complications has not been fully explored. We investigated the effects of islet transplantation on diabetic complications in a rat model of streptozotocin-induced diabetes.

Methods

Three groups of rats were used: healthy controls, diabetic and diabetic rats transplanted with microencapsulated islets at 2 months after diabetes induction, when neuropathy was detectable by a decrease in tail nerve conduction velocity (NCV) and impaired nociceptive thresholds. Blood glucose levels and body weight were measured weekly. The variables considered were: thermal (hot plate test) and mechanical sensitivity (Randal–Selitto paw withdrawal test), NCV and Na+, K+-ATPase activity in the sciatic nerve. At the end of the experiments hearts were removed for morphometric determination and myocyte number, and kidneys removed for histological examination.

Results

Islet transplantation in diabetic rats induced normoglycaemia in a few days, accompanied by a rapid rise in body weight and amelioration of impaired nociceptive thresholds, as well as normalisation of NCV and Na+, K+-ATPase, which were both about 25% below normal in diabetic rats. Myocyte loss was reduced (−34%) by islet transplantation and the observed mild kidney damage of diabetic rats was prevented.

Conclusions/interpretation

Besides controlling glycaemia, transplantation of microencapsulated pancreatic islets induced almost complete regression of neuropathy and prevented cardiovascular alterations.
Literature
1.
Fagot-Campagna A, Bourdel-Marchasson I, Simon D (2005) Burden of diabetes in an aging population: prevalence, incidence, mortality, characteristics and quality of care. Diabetes Metab 31(Spec No 2):5S35–5S52PubMedCrossRef
2.
Gregg EW, Engelgau MM, Narayan V (2002) Complications of diabetes in elderly people. BMJ 325:916–917CrossRefPubMed
3.
4.
Aneja A, Tang WH, Bansilal S, Garcia MJ, Farkouh ME (2008) Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 121:748–757CrossRefPubMed
5.
DCCT (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977–986CrossRef
6.
Vinik AI, Park TS, Stansberry KB, Pittenger GL (2000) Diabetic neuropathies. Diabetologia 43:957–973CrossRefPubMed
7.
Hoybergs YM, Meert TF (2007) The effect of low-dose insulin on mechanical sensitivity and allodynia in type I diabetes neuropathy. Neurosci Lett 417:149–154CrossRefPubMed
8.
9.
Kiguchi S, Imamura T, Ichikawa K, Kojima M (2004) Oxcarbazepine antinociception in animals with inflammatory pain or painful diabetic neuropathy. Clin Exp Pharmacol Physiol 31:57–64CrossRefPubMed
10.
Fang ZY, Prins JB, Marwick TH (2004) Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 25:543–567CrossRefPubMed
11.
Frustaci A, Kajstura J, Chimenti C et al (2000) Myocardial cell death in human diabetes. Circ Res 87:1123–1132PubMed
12.
Fiordaliso F, Bianchi R, Staszewsky L et al (2004) Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. J Mol Cell Cardiol 37:959–968CrossRefPubMed
13.
Cameron NE, Cotter MA, Archibald V, Dines KC, Maxfield EK (1994) Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. Diabetologia 37:449–459CrossRefPubMed
14.
Bianchi R, Buyukakilli B, Brines M et al (2004) Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A 101:823–828CrossRefPubMed
15.
Lauria G, Morbin M, Lombardi R et al (2003) Axonal swellings predict the degeneration of epidermal nerve fibers in painful neuropathies. Neurology 61:631–636PubMed
16.
Calcutt NA, Freshwater JD, O’Brien JS (2000) Protection of sensory function and antihyperalgesic properties of a prosaposin-derived peptide in diabetic rats. Anesthesiology 93:1271–1278CrossRefPubMed
17.
Leonelli E, Bianchi R, Cavaletti G et al (2007) Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: a multimodal analysis. Neuroscience 144:1293–1304CrossRefPubMed
18.
Pierson CR, Zhang W, Murakawa Y, Sima AA (2003) Insulin deficiency rather than hyperglycemia accounts for impaired neurotrophic responses and nerve fiber regeneration in type 1 diabetic neuropathy. J Neuropathol Exp Neurol 62:260–271PubMed
19.
DCCT (1995) The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 122:561–568
20.
Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M (1998) Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339:69–75CrossRefPubMed
21.
Gruessner RW, Sutherland DE, Troppmann C et al (1997) The surgical risk of pancreas transplantation in the cyclosporine era: an overview. J Am Coll Surg 185:128–144CrossRefPubMed
22.
Shapiro AM, Lakey JR, Ryan EA et al (2000) Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343:230–238CrossRefPubMed
23.
Kobayashi N (2008) Bioartificial pancreas for the treatment of diabetes. Cell Transplant 17:11–17CrossRefPubMed
24.
Fiorina P, Shapiro AM, Ricordi C, Secchi A (2008) The clinical impact of islet transplantation. Am J Transplant 8:1990–1997CrossRefPubMed
25.
Figliuzzi M, Plati T, Cornolti R et al (2006) Biocompatibility and function of microencapsulated pancreatic islets. Acta Biomater 2:221–227CrossRefPubMed
26.
Randall LO, Selitto JJ (1957) A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 111:409–419PubMed
27.
Cavaletti G, Minoia C, Schieppati M, Tredici G (1994) Protective effects of glutathione on cisplatin neurotoxicity in rats. Int J Radiat Oncol Biol Phys 29:771–776PubMed
28.
Scharschmidt BF, Keeffe EB, Blankenship NM, Ockner RK (1979) Validation of a recording spectrophotometric method for measurement of membrane-associated Mg- and NaK-ATPase activity. J Lab Clin Med 93:790–799PubMed
29.
Lauria G, Sghirlanzoni A, Lombardi R, Pareyson D (2001) Epidermal nerve fiber density in sensory ganglionopathies: clinical and neurophysiologic correlations. Muscle Nerve 24:1034–1039CrossRefPubMed
30.
Yorek MA, Coppey LJ, Gellett JS et al (2002) Effect of treatment of diabetic rats with dehydroepiandrosterone on vascular and neural function. Am J Physiol Endocrinol Metab 283:E1067–E1075PubMed
31.
Courteix C, Eschalier A, Lavarenne J (1993) Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 53:81–88CrossRefPubMed
32.
Sugimoto K, Rashid IB, Shoji M, Suda T, Yasujima M (2008) Early changes in insulin receptor signaling and pain sensation in streptozotocin-induced diabetic neuropathy in rats. J Pain 9:237–245CrossRefPubMed
33.
Scarpini E, Bianchi R, Moggio M, Sciacco M, Fiori MG, Scarlato G (1993) Decrease of nerve Na+, K(+)-ATPase activity in the pathogenesis of human diabetic neuropathy. J Neurol Sci 120:159–167CrossRefPubMed
34.
Brismar T, Sima AA, Greene DA (1987) Reversible and irreversible nodal dysfunction in diabetic neuropathy. Ann Neurol 21:504–507CrossRefPubMed
35.
36.
Kitano Y, Kuwabara S, Misawa S et al (2004) The acute effects of glycemic control on axonal excitability in human diabetics. Ann Neurol 56:462–467CrossRefPubMed
37.
Devigili G, Tugnoli V, Penza P et al (2008) The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain 131:1912–1925CrossRefPubMed
38.
Hirai A, Yasuda H, Joko M, Maeda T, Kikkawa R (2000) Evaluation of diabetic neuropathy through the quantitation of cutaneous nerves. J Neurol Sci 172:55–62CrossRefPubMed
39.
Chattopadhyay M, Walter C, Mata M, Fink DJ (2009) Neuroprotective effect of herpes simplex virus-mediated gene transfer of erythropoietin in hyperglycemic dorsal root ganglion neurons. Brain 132:879–888CrossRefPubMed
40.
Schmidt RE, Plurad SB, Olack BJ, Scharp DW (1983) The effect of pancreatic islet transplantation and insulin therapy on experimental diabetic autonomic neuropathy. Diabetes 32:532–540CrossRefPubMed
41.
Sima AA, Zhang WX, Tze WJ, Tai J, Nathaniel V (1988) Diabetic neuropathy in STZ-induced diabetic rat and effect of allogeneic islet cell transplantation. Morphometric analysis. Diabetes 37:1129–1136CrossRefPubMed
42.
Spadella CT, Machado JL, Caramori CA, Gregorio EA (2002) Successful islet transplantation does not prevent the development of neuropathy in alloxan-induced diabetic rats. Transplant Proc 34:1296–1300CrossRefPubMed
43.
Stroedter D, Schmidt T, Bretzel RG, Federlin K (1995) Glucose metabolism and left ventricular dysfunction are normalized by insulin and islet transplantation in mild diabetes in the rat. Acta Diabetol 32:235–243CrossRefPubMed
44.
Mourad JJ, Le Jeune S (2008) Blood pressure control, risk factors and cardiovascular prognosis in patients with diabetes: 30 years of progress. J Hypertens 26(Suppl 3):S7–S14CrossRefPubMed
45.
Giugliano D, Ceriello A, Paolisso G (1995) Diabetes mellitus, hypertension, and cardiovascular disease: which role for oxidative stress? Metabolism 44:363–368CrossRefPubMed
46.
Fiordaliso F, Li B, Latini R et al (2000) Myocyte death in streptozotocin-induced diabetes in rats is angiotensin II-dependent. Lab Invest 80:513–527PubMed
47.
Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W (2003) The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 107:992–995CrossRefPubMed
48.
Brown J, Sima AA, Tze WJ, Tai J, Thliveris JA (1989) The long-term effect of pancreatic islet allotransplantation on glomerular basement membrane thickening in experimental diabetes. J Diabetes Complications 3:35–39CrossRef
49.
Ekberg K, Brismar T, Johansson BL et al (2007) C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care 30:71–76CrossRefPubMed
50.
Hills CE, Al-Rasheed N, Willars GB, Brunskill NJ (2009) C-peptide reverses TGF-beta1-induced changes in renal proximal tubular cells: implications for treatment of diabetic nephropathy. Am J Physiol Renal Physiol 296:F614–F621CrossRefPubMed
Metadata
Title
Regression of diabetic complications by islet transplantation in the rat
Authors
A. Remuzzi
R. Cornolti
R. Bianchi
M. Figliuzzi
C. Porretta-Serapiglia
N. Oggioni
V. Carozzi
L. Crippa
F. Avezza
F. Fiordaliso
M. Salio
G. Lauria
R. Lombardi
G. Cavaletti
Publication date
01-12-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 12/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1537-y

Other articles of this Issue 12/2009

Diabetologia 12/2009 Go to the issue

Article

Overproduction of phosphoprotein enriched in diabetes (PED) induces mesangial expansion and upregulates protein kinase C-β activity and TGF-β1 expression

Article

Loss of islet sympathetic nerves and impairment of glucagon secretion in the NOD mouse: relationship to invasive insulitis

Short Communication

Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease

Article

Endosomal proteolysis of internalised [ArgA0]-human insulin at neutral pH generates the mature insulin peptide in rat liver in vivo

Article

Genetic influences on the insulin response of the beta cell to different secretagogues

Article

No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits